Endpoints News 27. Jan. 2026 Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
Endpoints News 21. Jan. 2026 Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’s